{
    "clinical_study": {
        "@rank": "148193", 
        "brief_summary": {
            "textblock": "To assess the efficacy of Saccharomyces boulardii (a nonpathogenic yeast) in producing a\n      significant reduction in diarrheal symptoms in HIV-infected patients with chronic diarrhea."
        }, 
        "brief_title": "Treatment of Patients With Human Immunodeficiency Virus (HIV)-Related Chronic Diarrhea With Saccharomyces Boulardii or Placebo: A Double Blind Trial", 
        "condition": [
            "Diarrhea", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Diarrhea", 
                "Immunologic Deficiency Syndromes"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Antiviral medication for HIV infection.\n\n        Patients must have:\n\n          -  Documented HIV infection.\n\n          -  Chronic diarrhea (for at least 1 month) that is either a manifestation or\n             complication of documented HIV infection.\n\n          -  Had a stool culture (Salmonella, Shigella, Campylobacter, and Clostridium difficile)\n             and stool analysis for ova and parasite (O/P X 3) within the past 2 months.\n\n          -  Failed antimicrobial treatment for diarrhea OR received no prior antimicrobials for\n             stool pathogens because stool cultures were negative.\n\n        Patients who are on antiviral medications for HIV infection must have received such\n        medication for at least 2 weeks and must remain on stable dose for weeks 1 and 2 of study.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Prior antiviral medication for HIV infection (if on such medication, must have\n             received it for at least 2 weeks).\n\n          -  Standard antimicrobial therapy for a documented positive gastrointestinal pathogen.\n\n        Exclusion Criteria\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Gastrointestinal medications that cause diarrhea (e.g., magnesium-containing\n             antacids, lactulose).\n\n          -  Maintenance antifungal medication for life-threatening fungal infections (other than\n             fluconazole <= 100 mg/day)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "100", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002088", 
            "org_study_id": "083A"
        }, 
        "intervention": {
            "intervention_name": "Saccharomyces boulardii", 
            "intervention_type": "Drug"
        }, 
        "keyword": [
            "Diarrhea", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "Saccharomyces"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seattle", 
                    "country": "United States", 
                    "state": "Washington", 
                    "zip": "98104"
                }, 
                "name": "Madison Clinic"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Treatment of Patients With Human Immunodeficiency Virus (HIV)-Related Chronic Diarrhea With Saccharomyces Boulardii or Placebo: A Double Blind Trial", 
        "overall_official": {
            "last_name": "Surawicz CM", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "reference": {
            "PMID": "8201735", 
            "citation": "McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, Melcher SA, Bowen KE, Cox JL, Noorani Z, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994 Jun 22-29;271(24):1913-8. Erratum in: JAMA 1994 Aug 17;272(7):518."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002088"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biocodex", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 1996"
    }, 
    "geocoordinates": {
        "Madison Clinic": "47.606 -122.332"
    }
}